Results 71 to 80 of about 46,312 (227)

Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease

Case Reports in Medicine, 2013
Introduction. Dabigatran is an oral direct thrombin inhibitor which has been approved for prophylaxis of stroke in patients with atrial fibrillation. The use of dabigatran etexilate increased rapidly due to many benefits.
Joonseok Kim, Mrinal Yadava, In Chul An, Abrar Sayeed, Heather S. Laird-Fick, Venu Gourineni, George S. Abela   +6 more
doaj   +1 more source

Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure

Medicina, 2019
Dabigatran etexilate is a direct oral anticoagulant (thrombin inhibitor) used for the prevention of stroke and systemic thromboembolic events in patients with permanent atrial fibrillation; prevention of venous thromboembolic events and deep veins ...
Gintautas Gumbrevičius, Gytė Damulevičienė, Vaidotas Galaunė, Milda Gumbrevičiūtė   +3 more
doaj   +1 more source

Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C [PDF]

, 2014
AIMS: Dabigatran is largely cleared by renal excretion. Renal function is thus a major determinant of trough dabigatran concentrations, which correlate with the risk of thromboembolic and haemorrhagic outcomes.
Berit P. Jensen, Daniel F. B. Wright, David M. Patterson, Evan J. Begg, Mary C. Wallace, Mei Zhang, Murray L. Barclay, Paul K. L. Chin, Rebecca L. Roberts   +8 more
core   +1 more source

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study [PDF]

, 2013
OBJECTIVE: Dabigatran was recently approved for anticoagulation in patients with atrial fibrillation (AF); data regarding real-world use, comparative effectiveness and safety are sparse. DESIGN: Pharmacoepidemiological cohort study.
Charlot, M., Fosbol, E. L., Gislason, G., Hansen, M. L., Hvidtfeldt, M. W., Karasoy, D., Kober, L., Lamberts, M., Lip, G. Y. H., Olesen, J. B., Sorensen, R., Torp-Pedersen, C., Weeke, P.   +12 more
core   +1 more source

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

European Heart Journal, 2019
Aims After percutaneous coronary intervention (PCI) in patients with atrial fibrillation, safety and efficacy with dabigatran dual therapy were evaluated in pre-specified subgroups of patients undergoing PCI due to acute coronary syndrome (ACS) or ...
J. Oldgren, P. Steg, S. Hohnloser, G. Lip, Takeshi Kimura, M. Nordaby, M. Brueckmann, E. Kleine, J. T. ten Berg, Deepak L. Bhatt, C. Cannon   +10 more
semanticscholar   +1 more source

Hemoclot Thrombin Inhibitor Assay and Expected Peak-Trough Levels of Dabigatran: A Multicenter Study

Frontiers in Cardiovascular Medicine, 2022
PurposeDabigatran concentrations monitoring are gaining importance of special situations, but limited data are available for the expected peak and trough levels. The hemoclot thrombin inhibitor (HTI) is dabigatran-calibrated quantitative determination of
Zhiyan Liu, Guangyan Mu, Qiufen Xie, Hanxu Zhang, Hanxu Zhang, Jie Jiang, Qian Xiang, Yimin Cui, Yimin Cui, Yimin Cui   +9 more
doaj   +1 more source

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2018
Background Whether non–vitamin K antagonist oral anticoagulants (NOACs) are superior to warfarin among Asians with nonvalvular atrial fibrillation remains unclear.
Y. Chan, L. See, H. Tu, Yung-Hsin Yeh, Shang-Hung Chang, Lung-Sheng Wu, Hsin-Fu Lee, Chun-Li Wang, Chang-Fu Kuo, C. Kuo   +9 more
semanticscholar   +1 more source

GRADE Evidence to Decision (EtD) frameworks : a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines [PDF]

, 2016
Funding: Work on this article has been partially funded by the European Commission FP7 Program (grant agreement 258583) as part of the DECIDE project. Sole responsibility lies with the authors; the European Commission is not responsible for any use that ...
the GRADE Working Group
core   +1 more source

DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS

Атеротромбоз, 2015
This article discusses the significant features and use of new oral anticoagulant dabigatran etexilate for the treatment of venous thromboembolic complications (VTC).
N. M. Vorobieva, E. P. Panchenko
doaj   +1 more source

Hemopericardium and Cardiac Tamponade Associated with Dabigatran Use [PDF]

, 2012
OBJECTIVE: To describe 2 cases of hemopericardium following treatment with dabigatran. CASE SUMMARIES: A 70-year-old male with a history of dabigatran use presented with cough, fatigue, and bloody stools.
Dy, Eliza A., Shiltz, Dane L.
core   +2 more sources